Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

BL22 immunotoxin

A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity. BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells. The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD22 recombinant immunotoxin BL22
BL22
BL22 Immunotoxin [RFB4(dsFv)-PE38]
RFB4(dsFv)-PE38 immunotoxin
Abbreviation:BL22
Code name:CAT 3888
CAT-3888
CAT3888
GCR-3888
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search